Moderna Inc. ($MRNA) Stock Forecast: Up 7.8% Today

What is Moderna Inc.?

Moderna is a biotechnology company recognized for its groundbreaking mRNA technology, particularly in vaccines and therapies. The stock witnessed significant upward movement today.

Why is Moderna Inc. going up?

MRNA stock is up 7.8% on Jun 3, 2026 19:51

• Moderna's shares surged by 8.1% today due to positive updates, including encouraging data on a new cancer vaccine, an expanded partnership for an ebolavirus vaccine, and the launch of an e-commerce platform.
• The bullish momentum was reinforced by UBS increasing its price target for Moderna, Inc. (MRNA) in anticipation of key pipeline catalysts, reflecting confidence in the company's future.
• Despite facing scrutiny over allegations regarding the efficacy of its RSV vaccine, investors appeared more focused on the positive developments and growth opportunities in the oncology market.
• Anticipated growth in the Acute Respiratory Distress Syndrome (ARDS) market and ongoing research by industry leaders likely contributed to the positive sentiment surrounding Moderna and its mRNA technology.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Moderna (NASDAQ:MRNA) Trading 8.1% Higher - Should You Buy?

Moderna (NASDAQ:MRNA) saw its shares trade up 8.1% during mid-day trading, reaching as high as $49.13. The increase occurred amid positive news including new cancer vaccine data, an expanded partnership for an ebolavirus vaccine, and the launch of an e-commerce platform. Despite some neutral analyst ratings, the company's financial metrics show both growth in revenue and negative earnings per share.

https://www.marketbeat.com/instant-alerts/moderna-nasdaqmrna-trading-81-higher-should-you-buy-2026-06-03/

Acute Respiratory Distress Syndrome Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Veru, Athersys, Inc, Histocell, BioXcellerator, Altor BioScience, Cartesian Therapeu

The Acute Respiratory Distress Syndrome (ARDS) market is projected to grow from approximately $1.7 billion in 2025 to $3.2 billion by 2036, at a CAGR of 3.8%. This growth is driven by increasing incidences of severe respiratory infections, critical care admissions, and advancements in critical care management, as well as ongoing research and development into novel therapies. Key market players like DelveInsight, Veru, and Edesa Biotech are developing new treatments, including HLCM051, paridiprubart, and GOHIBIC®, aiming to address the currently limited targeted therapies and complex pathophysiology of ARDS.

https://www.barchart.com/story/news/2261273/acute-respiratory-distress-syndrome-market-trends-innovation-and-future-growth-outlook-to-2036-delveinsight-veru-athersys-inc-histocell-bioxcellerator-altor-bioscience-cartesian-therapeu

Opportunities in the Oncology Market: Positioning for the Next Billion-Dollar Catalyst with BioNTech, Vidac Pharma, and Pfizer

The oncology market is experiencing significant growth, driven by an aging population and advancements in cancer treatment. This article highlights three key companies—BioNTech, Vidac Pharma, and Pfizer—that are strategically positioning themselves to capitalize on this multi-trillion-dollar market through various approaches including mRNA technology, metabolic targeting, and strategic acquisitions. Each company faces unique challenges and opportunities as they strive to develop innovative solutions in the evolving landscape of cancer therapy.

https://news.financial/comments/opportunities-for-returns-in-the-cancer-market-seizing-the-next-billion-dollar-trigger-with-biontech-vidac-pharma-and-pfizer

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna

Faruqi & Faruqi, LLP is investigating potential securities claims against Moderna (NASDAQ: MRNA) on behalf of investors who suffered losses exceeding $100,000 between January 18, 2023, and June 25, 2024. The investigation centers on allegations that Moderna made false or misleading statements regarding the efficacy of its RSV vaccine, mRNA-1345, which was found to be less effective than initially claimed. Investors are encouraged to contact the firm by the October 8, 2024 deadline to seek the role of lead plaintiff in the federal securities class action.

https://www.newsfilecorp.com/release/223661/SHAREHOLDER-ALERT-Faruqi-Faruqi-LLP-Investigates-Claims-on-Behalf-of-Investors-of-Moderna?lang=fr

UBS Lifts Valuation On Moderna, Inc. (MRNA) Ahead of Key Pipeline Catalysts

UBS raised its price target for Moderna, Inc. (MRNA) to $45 from $36, maintaining a Neutral rating, due to significant upcoming pipeline developments. The company's investigational mRNA influenza vaccine is scheduled for an FDA advisory committee evaluation on June 18, ahead of a regulatory decision deadline on August 5. This review is a critical step that could impact investor confidence in Moderna's respiratory vaccine pipeline and future commercial prospects.

https://www.insidermonkey.com/blog/ubs-lifts-valuation-on-moderna-inc-mrna-ahead-of-key-pipeline-catalysts-1773539/

Trending Today

Cardano ($ADA) Crypto Forecast: Down 5.1% Today

Ethereum ($ETH) Crypto Forecast: Down 5.8% Today

Newell Brands Inc. ($NWL) Stock Forecast: Up 5.7% Today

DocuSign Inc. ($DOCU) Stock Forecast: Down 5.0% Today

Salesforce.com Inc ($CRM) Stock Forecast: Down 5.0% Today

Moderna Inc. ($MRNA) Stock Forecast: Up 7.8% Today

Coinbase Global Inc. ($COIN) Stock Forecast: Down 6.0% Today

Honeywell International Inc. ($HON) Stock Forecast: Down 5.2% Today

Palantir Technologies Inc ($PLTR) Stock Forecast: Down 6.4% Today

Texas Roadhouse Inc. ($TXRH) Stock Forecast: Down 4.0% Today

Moderna Inc. Price History

12.04.2026 - MRNA Stock was down 6.7%

• Moderna (MRNA) faced a downturn today, potentially influenced by profit-taking following recent positive developments.
• The dip in Merck's stock value, attributed to a one-time charge stemming from an acquisition and a setback in its pipeline, may have impacted overall sentiments towards biotech equities, including Moderna.
• Investor attention could have shifted towards companies like Halozyme Therapeutics (HALO) with optimistic revenue projections, prompting a brief sell-off in Moderna shares.
• Market influencers within the biotech domain embracing cutting-edge technologies such as AI might have diverted focus away from Moderna, contributing to its bearish performance today.

03.05.2026 - MRNA Stock was up 7.8%

• Moderna's shares surged by 8.1% today due to positive updates, including encouraging data on a new cancer vaccine, an expanded partnership for an ebolavirus vaccine, and the launch of an e-commerce platform.
• The bullish momentum was reinforced by UBS increasing its price target for Moderna, Inc. (MRNA) in anticipation of key pipeline catalysts, reflecting confidence in the company's future.
• Despite facing scrutiny over allegations regarding the efficacy of its RSV vaccine, investors appeared more focused on the positive developments and growth opportunities in the oncology market.
• Anticipated growth in the Acute Respiratory Distress Syndrome (ARDS) market and ongoing research by industry leaders likely contributed to the positive sentiment surrounding Moderna and its mRNA technology.

29.04.2026 - MRNA Stock was up 5.1%

• Moderna's bullish movement today can be attributed to the positive sentiment surrounding its innovative mRNA technology and ongoing developments in the healthcare sector.
• The FDA advisory panel's recommendation to update COVID-19 vaccines for the XFG variant for the 2026-27 season could have boosted investor confidence in Moderna's capabilities to adapt to evolving virus strains.
• Despite insider selling and a cautious Wall Street sentiment, the potential for premium pricing and accelerated global market access for Moderna's plant-based drug targeting BPH and prostate cancer prevention could have sparked investor optimism.
• The acquisition of shares by institutional investors like Seven Grand Managers LLC further indicates confidence in Moderna's long-term growth prospects, potentially contributing to the bullish movement.

28.04.2026 - MRNA Stock was down 5.2%

• The bearish movement in Moderna's stock today can be attributed to:
• Perceived overbought conditions and technical indicators signaling reversals, leading traders to take short positions.
• Concerns about the stock being fundamentally overvalued, especially after its recent inclusion in the S&P 500 index.
• Lack of significant positive news catalysts to sustain the recent bullish momentum.
• Despite the bearish movement, the upcoming FDA advisory committee review for Moderna's mRNA flu shot and the company's preparations for a COVID-19 booster vaccine targeting the XFG strain in 2026–27 could potentially drive positive sentiment and future price movements.

03.05.2026 - MRNA Stock was up 5.5%

• Moderna (MRNA) saw a significant uptrend recently due to various factors:
• Bright prospects in the Acute Respiratory Distress Syndrome (ARDS) market, with growth projections fueled by innovative therapies being researched, potentially aligning with Moderna's unique vaccine development strategies.
• Improved valuation by UBS before key pipeline events, reflecting confidence in Moderna's future and growth potential.
• Despite ongoing challenges, optimism among investors remains high regarding Moderna's upcoming projects and regulatory milestones.
• Favorable industry sentiment in healthcare, particularly in fields like oncology and acute pain management, may have influenced the positive movement in Moderna's stock.

11.04.2026 - MRNA Stock was down 7.7%

• Despite a 6% surge earlier, Moderna's stock faced a bearish movement, potentially influenced by profit-taking following recent positive momentum.
• Initially boosted by renewed interest in Moderna's Hantavirus vaccine due to an outbreak, concerns about normalizing COVID-era revenue and GAAP losses may have contributed to the downturn.
• Investors seem to exercise caution due to uncertainties surrounding the revenue potential of the broader mRNA platform and the company's ability to sustain competitiveness against peers like Pfizer and Novavax in the vaccine sector.
• While the market sentiment towards Moderna remains positive, driven by upcoming Phase 3 readouts and a diverse pipeline, short-term volatility could linger as investors navigate challenges tied to the pandemic.

20.04.2026 - MRNA Stock was up 5.1%

• Moderna's stock surged by 20% due to emerging hantavirus cases, showcasing the market's confidence in the company's pandemic defense capabilities.
• The hantavirus scare not only boosted Moderna's stock but also highlighted the potential changes in vaccine-related regulatory environments, which could further benefit the company.
• Despite concerns about declining sales and profitability, Moderna's focus on infectious disease platforms and potential vaccine developments seems to have overshadowed these worries, driving the bullish movement in its stock today.

13.04.2026 - MRNA Stock was down 5.4%

• Moderna's stock experienced a bearish movement despite being ranked #1 on a list of Most Impactful Companies, showcasing its significant contributions to mRNA technology and public health.
• The company's Q1 earnings report with an EPS of ($3.40) may have contributed to the drop in share price, signaling potential investor concerns about profitability.
• Investors viewing Moderna as a pandemic hedge amidst reduced demand for Covid vaccines and regulatory challenges might have led to conflicting sentiments and added to the stock's volatility.
• The overall market sentiment towards biotech companies and vaccine manufacturers could have influenced Moderna's stock movement, with investors closely monitoring developments in the healthcare sector.

13.04.2026 - MRNA Stock was down 5.4%

• Moderna observed a downward trend in its stock price today despite investor confidence in its pandemic-related value. Possible reasons for this decline include:
• Decreased demand for Covid vaccines and regulatory challenges impacting investor optimism.
• Moderna faces uncertainties regarding its future trajectory and the viability of potential trading strategies related to the "hantavirus."
• News of Dominari Holdings' strong Q1 revenue growth and Sinovac Foundation's vaccine donations might have shifted investor focus away from Moderna, affecting its stock performance.
• Denison Mines' underwhelming earnings results and a poor financial health rating from InvestingPro could have contributed to negative overall market sentiment in the healthcare and biotech sectors, influencing Moderna's stock performance.

13.04.2026 - MRNA Stock was down 5.4%

• The stock of Moderna faced a downturn despite being acknowledged as a highly impactful company globally.
• Factors such as declining demand for COVID vaccines and a complex regulatory environment may have influenced the market's pessimistic view.
• Investors appear wary of Moderna's future trajectory, particularly as the company navigates critical decisions and places bets on a "hantavirus trade" to regain momentum.
• While Moderna has received acclaim for its mRNA technology innovations, current market sentiment seems more concerned with the company's present obstacles and uncertainties.

19.04.2026 - MRNA Stock was down 5.1%

• Moderna's bearish movement today may be linked to an insider sale by President Stephen Hoge, potentially unsettling investors and adding to stock volatility.
• The market sentiment around mRNA technology and the company's need to stabilize revenue post-pandemic could be contributing to the downward trend, despite positive growth from international partnerships and new vaccines.
• Investors may also be reacting to potential legal risks from intellectual property disputes, as mentioned in a recent conference audio transcript, which might be impacting Moderna's stock performance.
• The company's strong clinical and regulatory progress, beneficial for its long-term prospects, may not be sufficient to counter the immediate market factors influencing today's bearish movement.

19.04.2026 - MRNA Stock was down 6.9%

• Moderna's stock faced a downward trend subsequent to an insider selling 53,336 shares, conducted by President Stephen Hoge. This transaction heightened stock volatility, indicating investor sensitivity to internal activities.
• The market's adverse response to the insider sale potentially reflects uncertainties about Moderna's future growth trajectory and stability post-pandemic.
• Investor focus remains on Moderna's vaccine demand, progress in pipeline projects, and endeavors to stabilize revenue, all pivotal in determining stock performance.
• Noteworthy advancements from Wave Life Sciences regarding its AATD trial possibly impacted the biotech sector positively, while Moderna's descent was influenced by the insider transaction.